Original Article
Graft-Versus-Host Disease in Children Who Have Received a Cord-Blood or Bone Marrow Transplant from an HLA-Identical Sibling
N Engl J Med 2000; 342:1846-1854June 22, 2000
- Abstract
Background
Umbilical-cord blood as an alternative to bone marrow for hematopoietic stem-cell transplantation may lower the risk of graft-versus-host disease (GVHD).
Methods
We studied the records of 113 recipients of cord blood from HLA-identical siblings from the period from 1990 through 1997 and compared them with the records of 2052 recipients of bone marrow from HLA-identical siblings during the same period. The study population consisted of children 15 years of age or younger. We compared the rates of GVHD, hematopoietic recovery, and survival using Cox proportional-hazards regression to adjust for potentially confounding factors.
Results
Recipients of cord blood were younger than recipients of bone marrow (median age, 5 years vs. 8 years; P<0.001), weighed less (median weight, 17 kg vs. 26 kg; P<0.001), and were less likely to have received methotrexate for prophylaxis against GVHD (28 percent vs. 65 percent, P<0.001). Multivariate analysis demonstrated a lower risk of acute GVHD (relative risk, 0.41; P=0.001) and chronic GVHD (relative risk, 0.35; P=0.02) among recipients of cord-blood transplants. As compared with recovery after bone marrow transplantation, the likelihood of recovery of the neutrophil count and the platelet count was significantly lower in the first month after cord-blood transplantation (relative risk, 0.40 [P<0.001], and relative risk, 0.20 [P<0.001], respectively). Mortality was similar in the two groups (relative risk of death in the recipients of cord blood, 1.15; P=0.43).
Conclusions
Recipients of cord-blood transplants from HLA-identical siblings have a lower incidence of acute and chronic GVHD than recipients of bone marrow transplants from HLA-identical siblings.
Media in This Article
Figure 1
Outcomes among Recipients of a Cord-Blood Transplant from an HLA-Identical Sibling and Recipients of a Bone Marrow Transplant from an HLA-Identical Sibling.Table 1
Characteristics of the Recipients of Cord-Blood or Bone Marrow Transplants from HLA-Identical Siblings.Article Activity
- Article
Since the first successful transplantation of hematopoietic stem cells from umbilical-cord blood 11 years ago,1 banks have been established worldwide to supply cord blood as an alternative to bone marrow for transplantation. Globally, about 200 transplantations of cord blood from related donors and 1000 of cord blood from unrelated donors have been performed.2-7 The benefits of cord blood for transplantation are the immediate availability of cells, the absence of risk to the donor, and the low risk of transmitting infectious diseases. A potential advantage of cord blood over bone marrow is a lower risk of graft-versus-host disease (GVHD). The immunologic properties of lymphocytes from cord blood,8-12 as well as experimental results13,14 and clinical experience,2,5 suggest that the risk of GVHD may be lower after cord-blood transplantation than after bone marrow transplantation. Because transplantation of umbilical-cord blood has not been compared with transplantation of bone marrow after adjustment for factors known to influence the risk of GVHD, the issue is controversial.
Using data from two registries, we studied hematopoietic stem-cell transplantation in 113 children who received cord-blood transplants from HLA-identical siblings and 2052 children who received bone marrow transplants from HLA-identical siblings during the same period. We used a multivariate Cox regression analysis to adjust for factors that could potentially influence the risk of GVHD.
Methods
Collection of Data
Data on children who underwent cord-blood transplantation were provided by the Eurocord–Cord Blood Transplant Group (CBTG) and the International Bone Marrow Transplant Registry. Data on children who underwent bone marrow transplantation were provided by the International Bone Marrow Transplant Registry. Overlapping cases were identified, and the accuracy of the data was verified by both registries.
Eurocord–CBTG is an international registry in Paris that operates on behalf of the European Group for Blood and Marrow Transplantation. Participation is open to European and non-European centers that perform cord-blood transplantation, although most centers are in Europe. For each recipient, the registry collects, by questionnaire, data on the reasons for transplantation, specific characteristics of the cord-blood transplant, and outcomes. More than 100 transplantation centers participate.6 Participating centers report consecutive transplantations directly to the Eurocord–CBTG registry or to the registry of the European Group for Blood and Marrow Transplantation. Entries in both registries are checked by Eurocord–CBTG physicians at six-month intervals to eliminate overlap and to monitor compliance. Patients are followed longitudinally, with follow-up every six months. Submitted data are reviewed by two physicians, and the quality of the data is ensured by computerized checks for errors.
The International Bone Marrow Transplant Registry is a working group of more than 300 transplantation centers worldwide that contribute detailed data on allogeneic hematopoietic stem-cell transplantations to a statistical center at the Health Policy Institute of the Medical College of Wisconsin (in Milwaukee).15 Participating centers are required to report all transplantations consecutively; compliance is monitored by on-site audits. Patients are followed longitudinally, with yearly follow-up. Computerized checks for errors, physicians' reviews of submitted data, and on-site audits of participating centers ensure the quality of the data.
Inclusion Criteria
Our study involved patients who received a first transplant of allogeneic cord blood or bone marrow that had not been depleted of T cells; who were reported to Eurocord–CBTG, the International Bone Marrow Transplant Registry, or both; who were 15 years of age or younger at the time of transplantation; whose donor was an HLA-identical sibling; and who underwent transplantation between January 1, 1990, and December 31, 1997. A total of 113 recipients of a cord-blood transplant and 2052 recipients of a bone marrow transplant at 207 transplantation centers satisfied these criteria. At most, 60 of these transplantations have been described previously.2,5,16
Cord-Blood Transplantation
Patients
Table 1Table 1
Characteristics of the Recipients of Cord-Blood or Bone Marrow Transplants from HLA-Identical Siblings. shows the characteristics of the 113 children who underwent cord-blood transplantation. The median age was five years, and the median weight was 17 kg. Of the 61 of these children who underwent transplantation because of malignant disease, 47 had acute leukemia or chronic myelogenous leukemia. Of these, 21 percent had early leukemia (in first remission or first chronic phase), 60 percent had intermediate-stage leukemia (in second or subsequent remission or accelerated phase), and 19 percent had advanced leukemia (not in remission or in blast phase). The median length of time from diagnosis to transplantation was 25 months. The median period of follow-up was 27 months (range, 3 to 85).Transplantations
Twenty-seven patients who underwent cord-blood transplantation received total-body irradiation as part of the conditioning regimen (Table 1). Prophylaxis against GVHD consisted mainly of cyclosporine alone (58 percent) or in combination with glucocorticoids or other drugs, not including methotrexate (8 percent); 28 percent also received methotrexate. Methods of collection, cryopreservation, and storing of cord-blood units varied among centers. The median number of nucleated cells infused was 0.47×108 per kilogram of body weight (range, <1.0×108 to 3.6×108 per kilogram). Data on the numbers of colony-forming cells, CD3+ cells, and CD34+ cells in the graft were not available.
Bone Marrow Transplantation
Patients
Table 1 shows the characteristics of the 2052 children who received bone marrow transplants. The median age was eight years, and the median weight was 26 kg. Of the 1262 children who underwent transplantation for malignant disease, 1081 had acute leukemia or chronic myelogenous leukemia. Of these, 44 percent had early leukemia, 44 percent had intermediate-stage leukemia, and 12 percent had advanced leukemia. The median time from diagnosis to transplantation was 10 months. The median period of follow-up was 45 months (range, 1 to 101).
Transplantations
A total of 705 children who underwent bone marrow transplantation received total-body irradiation (Table 1). Prophylaxis against GVHD consisted mainly of cyclosporine in combination with methotrexate, with or without glucocorticoids (65 percent). Twenty percent received cyclosporine alone. The median number of nucleated cells infused was 3.5×108 per kilogram (range, <1.0×108 to 41×108 per kilogram).
End Points
Grade II, III, or IV acute GVHD was the primary end point of our study. Acute GVHD was diagnosed and graded with the use of standard criteria by the physicians who performed the transplantations at each center17; only patients who survived at least 21 days were evaluated. Chronic GVHD was diagnosed according to standard criteria18; only patients who survived at least 90 days with sustained engraftment were evaluated.
Neutrophil recovery and platelet recovery were analyzed separately in patients who survived for at least 21 days after transplantation. Indicators of recovery were a neutrophil count of at least 500 per cubic millimeter for three consecutive days and a platelet count of at least 20×103 per cubic millimeter that was maintained for seven consecutive days without platelet transfusions. Data on patients who underwent a second transplantation because of nonengraftment were censored at the time of conditioning for the second procedure or, if no additional conditioning was administered, at the time of the second transplantation. For analyses of survival, data on patients were censored at the time of the last follow-up visit.
Statistical Analysis
For both groups, we compared variables related to the transplant recipients, the underlying diseases, and the transplantation procedures, using the chi-square statistic for categorical variables and the Mann–Whitney test for continuous variables. The probability of survival was estimated by the Kaplan–Meier method; the log-rank test was used for univariate comparisons. Cumulative incidence curves were used to calculate the probability of acute GVHD, chronic GVHD, and neutrophil and platelet recovery.19 The associations of the type of graft with outcomes were evaluated in multivariate analyses, with the use of Cox proportional-hazards regression to adjust for differences in potentially confounding variables between the cohorts.
The variables considered were the recipient's age, weight, and status with respect to cytomegalovirus (determined by serologic testing); the sex of the recipient and the donor, and the degree of ABO matching; the type and duration of the underlying disease; the conditioning regimen; the type of prophylaxis against GVHD; the use or nonuse of granulocyte colony-stimulating factor, granulocyte–macrophage colony-stimulating factor, or both to hasten the recovery of neutrophils; and the dose of nucleated cells infused. Only factors significantly associated with an outcome (P<0.05) were retained in the final models. The absence of a factor from the final models indicates that there was no significant association with the risk of the outcome described.
For each outcome and covariate, the assumption of proportional hazards was tested with the use of time-dependent covariates. When the test indicated differential effects over time (nonproportional hazards), we constructed models in which the interval after transplantation was divided into two periods, and we used the maximized partial-likelihood method to find the most appropriate break-point.20 For these variables, we determined the relative risks for each of the periods. A forward stepwise method of selecting variables at a significance level of less than 0.05 was used to identify covariates other than the type of graft that were associated with outcome. In each step, the covariate for the type of graft was included in the model. First-order interactions between the type of graft and significant covariates were considered. We tested the overall effects of covariates using Wald's test. To determine the effects of the transplantation center, we tested a random-effects model21; there was no evidence that center-related effects confounded our previous findings. All P values are two-sided.
Results
Patients
Recipients of cord-blood transplants tended to be younger (P<0.001) and weigh less (P<0.001) than recipients of bone marrow transplants (Table 1). The proportion of patients with malignant or nonmalignant diseases was similar in both groups (P=0.11). However, the proportion of patients with acute leukemia was smaller and the proportion with congenital disorders of hematopoiesis was larger in the cord-blood group (P<0.01).
Transplantation
The interval between diagnosis and transplantation was longer for recipients of cord-blood transplants than for recipients of bone marrow transplants (P< 0.001). The cord-blood group had more pairs of female donors and female recipients and fewer pairs of male donors and female recipients than the bone marrow group (P<0.001). The cord-blood group also had more donor–recipient pairs with major ABO mismatches (P<0.001). Substantially fewer recipients of cord-blood transplants received methotrexate for prophylaxis against GVHD (P<0.001). Hematopoietic growth factors were used more frequently after cord-blood transplantation (P<0.001). Cord-blood grafts contained almost one log fewer nucleated cells than did the bone marrow grafts (P<0.001).
Acute and Chronic GVHD
In the univariate analysis, which was not adjusted for differences among patients, the cumulative incidence of grade II, III, and IV acute GVHD was significantly lower after cord-blood transplantation: 14 percent (95 percent confidence interval, 8 to 22 percent), as compared with 24 percent (95 percent confidence interval, 22 to 26 percent) after bone marrow transplantation (P=0.02) (Figure 1AFigure 1
Outcomes among Recipients of a Cord-Blood Transplant from an HLA-Identical Sibling and Recipients of a Bone Marrow Transplant from an HLA-Identical Sibling.). Acute GVHD was less severe in patients who received cord-blood transplants. Among 107 cord-blood recipients who could be evaluated (those who survived at least 21 days after transplantation), 18 had grade I acute GVHD (17 percent), 13 had grade II acute GVHD (12 percent), 2 had grade III acute GVHD (2 percent), and none had grade IV acute GVHD. In contrast, among 2012 bone marrow recipients who could be evaluated, 413 had grade I acute GVHD (21 percent), 314 had grade II acute GVHD (16 percent), 111 had grade III acute GVHD (6 percent), and 73 had grade IV acute GVHD (4 percent) (P=0.004). Similar differences in severity were found when the manifestations of GVHD in the skin, gut, and liver were analyzed separately (data not shown).Chronic GVHD affected 5 of 93 recipients of cord-blood transplants who survived more than 90 days (5 percent) and 257 of 1779 recipients of bone marrow transplants who survived at least 90 days (14 percent). The three-year cumulative incidence of chronic GVHD was 6 percent (95 percent confidence interval, 2 to 13 percent) after cord-blood transplantation and 15 percent (95 percent confidence interval, 13 to 17 percent) after bone marrow transplantation (P= 0.02) (Figure 1B).
Results were similar in the multivariate analysis (Table 2Table 2
Results of Multivariate Analyses in Which Outcomes Were Compared between Recipients of Cord-Blood Transplants and Recipients of Bone Marrow Transplants.). After adjustment for relevant risk factors, the risk of acute and chronic GVHD was significantly lower after cord-blood transplantation than after bone marrow transplantation. The relative risk of grade II, III, or IV acute GVHD and chronic GVHD in the cord-blood group, as compared with the bone marrow group, was 0.41 (95 percent confidence interval, 0.24 to 0.70; P=0.001) and 0.35 (95 percent confidence interval, 0.14 to 0.85; P=0.02), respectively. Other variables associated with a lower risk of acute GVHD were nonmalignant disease, a shorter interval between diagnosis and transplantation, absence of a major ABO mismatch, and the use of methotrexate in combination with cyclosporine for prophylaxis against GVHD. Other variables associated with a lower risk of chronic GVHD were an age of less than 10 years, nonmalignant disease, and the use of methotrexate in combination with cyclosporine for prophylaxis against GVHD.Hematopoietic Recovery
The median number of days required for the neutrophil count to reach at least 500 per cubic millimeter after cord-blood transplantation was 26, as compared with 18 for bone marrow transplantation. The cumulative incidence of a neutrophil count of at least 500 per cubic millimeter 60 days after transplantation was 89 percent (95 percent confidence interval, 82 to 94 percent) after cord-blood transplantation and 98 percent (95 percent confidence interval, 97 to 99 percent) after bone marrow transplantation (P<0.001) (Figure 1C). The median time required for the platelet count to reach at least 20×103 per cubic millimeter was 44 days after cord-blood transplantation and 24 days after bone marrow transplantation. The cumulative incidence of such a platelet count at day 180 was 86 percent (95 percent confidence interval, 78 to 92 percent) after cord-blood transplantation and 96 percent (95 percent confidence interval, 94 to 97 percent) after bone marrow trans-plantation (P<0.001).
In the multivariate analysis, the relative risk of neutrophil recovery in the first month after cord-blood transplantation as compared with bone marrow transplantation was 0.40 (95 percent confidence interval, 0.32 to 0.51; P<0.001) (Table 2). Patients who received a cord-blood transplant had a significantly longer time to platelet recovery in the early period after transplantation than patients who received a bone marrow transplant (relative risk, 0.20; 95 percent confidence interval, 0.13 to 0.29; P<0.001). However, among patients who lived 34 days after the procedure and still had thrombocytopenia, the likelihood that the platelet count would return toward normal was similar in both groups (relative risk, 0.98; 95 percent confidence interval, 0.73 to 1.32; P=0.92) (Table 2). Other factors significantly associated with delayed neutrophil recovery were malignant disease, female recipient, presence of a major ABO mismatch, use of cyclosporine and methotrexate as prophylaxis against GVHD, and no use of post-transplantation growth factors. Factors significantly associated with delayed platelet recovery were malignant disease, younger age of recipient, prophylaxis against GVHD with cyclosporine and methotrexate, and the use of post-transplantation growth factors.
Overall Survival
One hundred days after transplantation, the mortality rate was 14 percent (95 percent confidence interval, 8 to 22 percent) in the cord-blood group and 12 percent (95 percent confidence interval, 11 to 13 percent) in the bone marrow group (P=0.36). The three-year probability of survival was 64 percent (95 percent confidence interval, 53 to 74 percent) in the cord-blood group and 66 percent (95 percent confidence interval, 64 to 68 percent) in the bone marrow group (P=0.93). Among patients who received transplants for malignant disease, the three-year survival rate was 46 percent (95 percent confidence interval, 31 to 62 percent) for 61 patients given cord blood and 55 percent (95 percent confidence interval, 52 to 58 percent) for 1263 patients given bone marrow (P=0.69) (Figure 1D). Among patients who underwent transplantation for nonmalignant diseases, the three-year survival rate was 86 percent (95 percent confidence interval, 75 to 94 percent) for 52 given cord blood and 84 percent (95 percent confidence interval, 81 to 87 percent) for 789 given bone marrow (P=0.82) (Figure 1D).
In the multivariate analysis, there was no significant difference between the cord-blood group and the bone marrow group in terms of survival after transplantation (relative risk of death, 1.15; 95 percent confidence interval, 0.81 to 1.65; P=0.43) (Table 2). Covariates significantly associated with an increased risk of death in both cohorts were an age older than 10 years, malignant disease, and seropositivity for cytomegalovirus in the recipient.
Causes of Death
Thirty-one of 113 recipients of cord-blood transplants (27 percent) and 648 of 2052 recipients of bone marrow transplants (32 percent) died. Persistent or recurrent malignant disease was the most frequently reported primary cause of death in both groups (accounting for 48 percent of deaths in the cord-blood group and 49 percent in the bone marrow group). In the cord-blood group, there were two deaths from graft failure (6 percent of the deaths), seven deaths from infection (all in the first 100 days after transplantation) (23 percent), three deaths from hemorrhage (10 percent), and four deaths from unknown causes (13 percent). In the bone marrow group, there were 23 deaths from graft failure (4 percent), 72 deaths from GVHD (11 percent), 113 deaths from infection (61 of which were in the first 100 days after transplantation) (17 percent), 46 deaths from organ failure (7 percent), 24 deaths from hemorrhage (4 percent), and 54 deaths from other or unknown causes (8 percent). Deaths related to infection from any cause and hemorrhage were more common in the cord-blood group, whereas deaths related to GVHD, interstitial pneumonitis, and organ failure were more common in the bone marrow group (P=0.05 by Fisher's exact test). The numbers of relapse-related deaths were similar in the two groups.
Discussion
Several reports have suggested that cord-blood transplantation is associated with a lower incidence of acute and chronic GVHD than is bone marrow transplantation.2-5,7,22 However, because the incidence of GVHD correlates strongly with age, and because most cord-blood transplantations are performed in children, it is not clear whether or by how much the incidence differs in comparable groups of recipients of bone marrow or cord-blood transplants. Comparing the risk of GVHD between recipients of cord-blood transplants and recipients of bone marrow transplants from unrelated donors is complicated by differences in donor–recipient histocompatibility that may not apply to sibling donor–recipient pairs and by the methods used to ascertain histocompatibility.
In this registry-based study, we found that after adjustment for factors that influence the risk of GVHD, the incidence of acute and chronic GVHD was lower after cord-blood transplantation than after bone marrow transplantation in children who received cells from HLA-identical sibling donors.
In our study, some of the differences between recipients of cord-blood transplants and recipients of bone marrow transplants, such as the length of time from diagnosis to transplantation, might not be expected to confound comparisons of the risk of GVHD. However, there were also differences in factors that influence this risk, such as the younger age of the recipients of cord blood (which would be expected to result in a decreased risk) or the fact that fewer patients in the cord-blood group than in the bone marrow group received a combination of methotrexate and cyclosporine as prophylaxis against GVHD (which would be expected to result in an increased risk).23,24
We used multivariate regression models to take in-to account the independent effects of each potential prognostic factor. These analyses confirmed that the risk of GVHD was lower after transplantation with cord blood than after transplantation with bone marrow. The difference between cord blood and bone marrow may be due to immunologic properties of umbilical-cord T cells that reduce their capacity to induce GVHD.8,11,25-28
In our study, overall survival did not differ significantly between recipients of cord-blood transplants and recipients of bone marrow transplants, regardless of the indication for transplantation and despite a slower rate of engraftment after cord-blood transplantation. Overall, the data suggest that umbilical-cord blood is as effective as bone marrow as a source of hematopoietic stem cells for children who receive transplants from HLA-identical siblings.
Few patients have umbilical-cord blood from an HLA-identical sibling available for transplantation; the real potential for this procedure lies in its use for unrelated recipients. Comparisons similar to those made in this study are needed for transplants of cord blood and bone marrow from unrelated donors, especially because the differences between such groups in terms of the characteristics of the patients may be even more pronounced than in the groups of patients who received transplants from related donors. Such comparisons will also require careful consideration of the degree of histocompatibility between donor and recipient.
In conclusion, children who received cord-blood transplants from HLA-identical siblings had a lower risk of acute and chronic GVHD and longer times to neutrophil and platelet recovery than children who received bone marrow transplants from HLA-identical siblings. These results justify the systematic collection of cord blood in families with a child affected by a disease that can be treated successfully by allogeneic transplantation of hematopoietic stem cells. The results also support further exploration of cord blood as a source of stem cells for transplants from unrelated donors.
Supported by a Biomed II grant from the European Union (Eurocord BMH4CT96); a grant from the European Group for Blood and Marrow Transplantation; Public Health Service grants (P01-CA-40053, U24-76518, and P01-CA-65493) from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute; and grants from Alpha Therapeutic, Amgen, anonymous sources, Baxter Fenwal, Berlex Laboratories, Bio Whitakker, Blue Cross and Blue Shield Association, the Lynde and Harry Bradley Foundation, Bristol-Myers Squibb, Cell Therapeutics, Centeon, the Center for Advanced Studies in Leukemia, the Children's Cancer Research Fund, Chimeric Therapies, Chiron Therapeutics, the Charles E. Culpeper Foundation, the Eleanor Naylor Dana Charitable Trust, the Eppley Foundation for Research, Genentech, Human Genome Sciences, Immunex, the Kettering Family Foundation, Kirin Brewery, the Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation, Herbert H. Kohl Charities, Nada and Herbert P. Mahler Charities, the Milstein Family Foundation, the Milwaukee Foundation/Elsa Schoeneich Research Fund, NeXstar Pharmaceuticals, the Samuel Roberts Noble Foundation, Novartis Pharmaceuticals, Orphan Medical, Ortho Biotech, the John Oster Family Foundation, the Jane and Lloyd Pettit Foundation, the Alirio Pfiffer Bone Marrow Transplant Support Association, Pfizer, the RGK Foundation, Roche Laboratories, Rockwell Automation Allen Bradley, SangStat Medical, Schering, Schering-Plough Oncology, Searle, Sequus Pharmaceuticals, SmithKline Beecham Pharmaceutical, the Stackner Family Foundation, the Starr Foundation, the Joan and Jack Stein Foundation, SyStemix, United Resource Networks, and Wyeth–Ayerst Laboratories.
Source Information
From the Eurocord–Cord Blood Transplant Group, Hôpital Saint Louis and University of Paris, Paris (V.R., E.G.); the University of Minnesota School of Medicine, Minneapolis (J.E.W.); and the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee (K.A.S., J.P.K., M.-J.Z., M.M.H.). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Address reprint requests to Dr. Horowitz at the IBMTR/ABMTR Statistical Center, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226; or at marymh@mcw.edu.
Other members of the committee are listed in the Appendix.
Appendix
In addition to the authors, other members of the Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources who participated in this study were as follows: M.M. Abecasis, Instituto Portugues de Oncologia, Lisbon, Portugal; B.J. Bolwell, Cleveland Clinic Foundation, Cleveland; M.S. Cairo, Georgetown University Medical Center, Washington, D.C.; M.H. Carabasi, University of Alabama, Birmingham; M.J. Cowan, University of California, San Francisco; R.P. Gale, Center for Advanced Studies in Leukemia, Los Angeles; G. Hale, St. Jude Children's Research Hospital, Memphis, Tenn.; R.E. Harris, Children's Hospital Medical Center, Cincinnati; P.J. Henslee-Downey, University of South Carolina, Columbia; J.M. Hows, University of Bristol, Bristol, United Kingdom; S. Kato, Tokai University Hospital, Kanagawa, Japan; N.A. Kernan, Memorial Sloan-Kettering Cancer Center, New York; J. Kurtzberg, Duke University Medical Center, Durham, N.C.; J. Lister, Western Pennsylvania Cancer Institute, Pittsburgh; F. Locatelli, University of Pavia, Pavia, Italy; G. Michel, Groupe Hospitalier de la Timone, Marseilles, France; A. Nagler, Hadassah Hebrew University Hospital, Jerusalem, Israel; J.J. Ortega, Hospital Infantil Vall d'Hebron, Barcelona, Spain; R. Pasquini, Hospital de Clinicas, Curitiba, Brazil; T. Radde-Stepaniak, National Marrow Donor Program, Minneapolis; O. Ringdén, Karolinska Institute, Huddinge, Sweden; G. Souillet, Hôpital Debrousse, Lyons, France; M.E. Trigg, A.I. duPont Hospital for Children, Wilmington, Del.; M.R. Vowels, Sydney Children's Hospital, Randwick, New South Wales, Australia; J.R. Wingard, University of Florida, Gainesville; and L.C. Yu, Children's Hospital, Louisiana State University, New Orleans.
- References
References
1
Gluckman E ,Broxmeyer HA ,Auerbach AD , et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178
Full Text | Web of Science | Medline2
Wagner JE ,Kernan NA ,Steinbuch M ,Broxmeyer HE ,Gluckman E . Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995;346:214-219
CrossRef | Web of Science | Medline3
Kurtzberg J ,Laughlin M ,Graham ML , et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-166
Full Text | Web of Science | Medline4
Wagner JE ,Rosenthal J ,Sweetman R , et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795-802
Web of Science | Medline5
Gluckman E ,Rocha V ,Boyer-Chammard A , et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337:373-381
Full Text | Web of Science | Medline6
Gluckman E, Rocha V, Chastang C. Ham Wasserman Lecture: cord blood hematopoietic stem cells: biology and transplantation. Hematology 1998;1-14.
7
Rubinstein P ,Carrier C ,Scaradavou A , et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-1577
Full Text | Web of Science | Medline8
Harris DT ,Shumacher MJ ,Locascio J , et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci U S A 1992;89:10006-10010
CrossRef | Web of Science | Medline9
Risdon G ,Gaddy J ,Stehman FB ,Broxmeyer HE . Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol 1994;154:14-24
CrossRef | Web of Science | Medline10
Roncarolo MG ,Bigler M ,Ciuti E ,Martino S ,Tovo PA . Immune responses by cord blood cells. Blood Cells 1994;20:573-585
Medline11
Madrigal JA ,Cohen SB ,Gluckman E ,Charron DJ . Does cord blood transplantation result in lower graft-versus-host disease? It takes more than two to tango. Hum Immunol 1997;56:1-5
CrossRef | Web of Science | Medline12
Garderet L ,Dulphy N ,Douay C , et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood 1998;91:340-346
Web of Science | Medline13
de La Selle V ,Gluckman E ,Bruley-Rosset M . Newborn blood can engraft adult mice without inducing graft-versus-host disease across non H-2 antigens. Blood 1996;87:3977-3983
Web of Science | Medline14
de La Selle V ,Gluckman E ,Bruley-Rosset M . Graft-versus-host disease and graft-versus-leukemia effect in mice grafted with peripheral newborn blood. Blood 1998;92:3968-3975
Web of Science | Medline15
Horowitz MM, Bortin MM. The role of registries in evaluating the results of bone marrow transplantation. In: Treleaven JG, Barrett AJ, eds. Bone marrow transplantation in practice. London: Churchill Livingstone, 1992:367-77.
16
Locatelli F ,Rocha V ,Chastang C , et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 1999;93:3662-3671
Web of Science | Medline17
Glucksberg H ,Storb R ,Fefer A , et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304
CrossRef | Web of Science | Medline18
Storb R ,Prentice RL ,Sullivan KM , et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983;98:461-466
Web of Science | Medline19
Gooley TA ,Leisenring W ,Crowley JA ,Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706
CrossRef | Web of Science | Medline20
Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag, 1997:334-6.
21
Andersen PK ,Klein JP ,Zhang MJ . Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 1999;18:1489-1500
CrossRef | Web of Science | Medline22
Cairo MS ,Wagner JE . Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997;90:4665-4678
Web of Science | Medline23
Deeg HJ ,Storb R ,Thomas ED , et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985;65:1325-1334
Web of Science | Medline24
Ringden O ,Horowitz MM ,Sondel P , et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993;81:1094-1101
Web of Science | Medline25
Garban F ,Ericson M ,Roucard C , et al. Detection of empty HLA class II molecules on cord blood B cells. Blood 1996;87:3970-3976
Web of Science | Medline26
Chalmers IM ,Janossy G ,Contreras M ,Navarrete C . Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998;92:11-18
Web of Science | Medline27
Truman JP ,Garban F ,Choqueux C ,Charron D ,Mooney N . HLA class II signaling mediates cellular activation and programmed cell death. Exp Hematol 1996;24:1409-1415
Web of Science | Medline28
Truman JP ,Choqueux C ,Tschopp J , et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood 1997;89:1996-2007
Web of Science | Medline
- Citing Articles (261)
Citing Articles
1
Syh-Jae Lin, Dah-Chin Yan, Yen-Chang Lee, Hsiu-Shan Hsiao, Pei-Tzu Lee, Yu-Wen Liang, Ming-Ling Kuo. (2011) Umbilical Cord Blood Immunology—Relevance to Stem Cell Transplantation. Clinical Reviews in Allergy & Immunology
CrossRef2
Martha Luevano, Mehri Daryouzeh, Rehab Alnabhan, Sergio Querol, Salim Khakoo, Alejandro Madrigal. (2011) The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Human Immunology
CrossRef3
Marina Buzzi, Francesco Alviano, Diana Campioni, Marina Stignani, Loredana Melchiorri, Antonella Rotola, Pierluigi Tazzari, Francesca Ricci, Cristiana Vaselli, Adriana Terzi, Pasquale P. Pagliaro, Antonio Cuneo, Francesco Lanza, Andrea Bontadini, Olavio R. Baricordi, Roberta Rizzo. (2011) Umbilical cord blood CD34+cell–derived progeny produces human leukocyte antigen–G molecules with immuno-modulatory functions. Human Immunology
CrossRef4
E. Gluckman. (2011) Milestones in umbilical cord blood transplantation. Blood Reviews 25:6, 255-259
CrossRef5
C. E. Stevens, C. Carrier, C. Carpenter, D. Sung, A. Scaradavou. (2011) HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood 118:14, 3969-3978
CrossRef6
Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S. Cairo, Monica Bhatia, Joanne Kurtzberg, John R. Wingard, Anders Fasth, Luca Lo Nigro, Mouhab Ayas, Duncan Purtill, Karim Boudjedir, Wagnara Chaves, Mark C. Walters, John Wagner, Eliane Gluckman, Vanderson Rocha. (2011) Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. Biology of Blood and Marrow Transplantation 17:9, 1375-1382
CrossRef7
Tomohiro Morio, Yoshiko Atsuta, Daisuke Tomizawa, Tokiko Nagamura-Inoue, Koji Kato, Tadashi Ariga, Keisei Kawa, Kazutoshi Koike, Hisamichi Tauchi, Michiko Kajiwara, Toshiro Hara, Shunichi Kato, . (2011) Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. British Journal of Haematology 154:3, 363-372
CrossRef8
Young-June Kim, Hal E. Broxmeyer. (2011) Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Critical Reviews in Oncology/Hematology 79:2, 112-126
CrossRef9
Caron A. Jacobson, Amin T. Turki, Sean M. McDonough, Kristen E. Stevenson, Haesook T. Kim, Grace Kao, Maria I. Herrera, Carol G. Reynolds, Edwin P. Alyea, Vincent T. Ho, John Koreth, Philippe Armand, Yi-Bin Chen, Karen Ballen, Robert J. Soiffer, Joseph H. Antin, Corey S. Cutler, Jerome Ritz. (2011) Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation
CrossRef10
Eliane Gluckman, Annalisa Ruggeri, Fernanda Volt, Renato Cunha, Karim Boudjedir, Vanderson Rocha. (2011) Milestones in umbilical cord blood transplantation. British Journal of Haematology 154:4, 441-447
CrossRef11
T. Chandra, S. Afreen, A. Kumar, U. Singh. (2011) Correlation of Birth Weight of Full Term Infants with Cord Blood derived CD34+ Cells Concentration. Journal of Tropical Pediatrics
CrossRef12
Giovanni Fernando Torelli, Roberta Maggio, Nadia Peragine, Sabina Chiaretti, Maria Stefania Propris, Barbarella Lucarelli, Maria Screnci, Maria Grazia Mascolo, Filippo Milano, Anna Paola Iori, Gabriella Girelli, Anna Guarini, Robin Foà. (2011) Functional analysis and gene expression profile of umbilical cord blood regulatory T cells. Annals of Hematology
CrossRef13
Prakash Satwani, Carmella van de Ven, Janet Ayello, Dustin Cairo, Lynn L. Simpson, Laxmi Baxi, Mitchell S. Cairo. (2011) Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy 13:6, 730-738
CrossRef14
K Ishiyama, T Katagiri, T Hoshino, T Yoshida, M Yamaguchi, S Nakao. (2011) Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplantation 46:6, 863-869
CrossRef15
Michael J. Burke, Rachel Isaksson Vogel, Sanyukta K. Janardan, Claudio Brunstein, Angela R. Smith, Jeffrey S. Miller, Daniel Weisdorf, John E. Wagner, Michael R. Verneris. (2011) Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation 17:6, 831-840
CrossRef16
N S Majhail, C G Brunstein, R Shanley, K Sandhu, B McClune, B Oran, E D Warlick, J E Wagner, D J Weisdorf. (2011) Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplantation
CrossRef17
A Alsultan, R H Giller, D Gao, J Bathurst, E Hild, L Gore, N K Foreman, A Keating, R R Quinones. (2011) GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplantation 46:5, 668-675
CrossRef18
Koji Kato, Ayami Yoshimi, Etsuro Ito, Kentaro Oki, Jun Hara, Yoshihisa Nagatoshi, Akira Kikuchi, Ryoji Kobayashi, Tokiko Nagamura-Inoue, Shunro Kai, Hiroshi Azuma, Minoko Takanashi, Keiichi Isoyama, Shunichi Kato. (2011) Cord Blood Transplantation from Unrelated Donors for Children with Acute Lymphoblastic Leukemia in Japan: The Impact of Methotrexate on Clinical Outcomes. Biology of Blood and Marrow Transplantation
CrossRef19
Cécile Rénard, Vincent Barlogis, Valérie Mialou, Claire Galambrun, Delphine Bernoux, Marie Pierre Goutagny, Laurence Glasman, Anderson Dieudonné Loundou, Françoise Poitevin-Later, Françoise Dignat-George, Valérie Dubois, Christophe Picard, Christian Chabannon, Yves Bertrand, Gérard Michel. (2011) Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. British Journal of Haematology 152:3, 322-330
CrossRef20
Hiroto Narimatsu. (2011) Immune Reactions following Cord Blood Transplantations in Adults. Stem Cells International 2011, 1-6
CrossRef21
Marilena Lupu, Markus Khalil, Eugen Andrei, Florin Iordache, Kurt Pfannkuche, Klaus Neef, Adriana Georgescu, Cosmin Buzila, Konrad Brockmeier, Horia Maniu, Jürgen Hescheler. (2011) Integration Properties of Wharton’s Jelly-derived Novel Mesenchymal Stem Cells into Ventricular Slices of Murine Hearts. Cellular Physiology and Biochemistry 28:1, 63-76
CrossRef22
Afonso Celso Vigorito, Luis Fernando da Silva Bouzas, Maria Cláudia Rodrigues Moreira, Vaneuza Araújo Moreira Funke, Virgílio Antonio Rensi Colturato, Andréia Pedro, Clarissa Vasconcellos de Souza, Elenaide Coutinho Nunes, Eliana Cristina Martins Miranda, Kátia Camacho, Marcos Augusto Mauad, Maria Elvira Pizzigatti Correa, Márcia de Matos Silva, Mair Pedro de Sousa, Rita de Cássia Barbosa da Silva Tavares, Stephanie Joi Lee, Mary Evelyn Dantas Flowers. (2011) A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria. Revista Brasileira de Hematologia e Hemoterapia 33:4, 283-289
CrossRef23
Eun Kim, Yun Chang, Soo Choi, Jin Kim, Hey Yoo, So Ahn, Dong Sung, Soo Kim, Ye Park, Won Park. (2011) Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respiratory Research 12:1, 108
CrossRef24
Hee Jo Baek, Hoon Kook, Dong Kyun Han, Tai Ju Hwang. (2011) Hematopoietic Stem Cell Transplantation in Children with Leukemia: A Single Institution Experience with Respect to Donors. Journal of Korean Medical Science 26:12, 1548
CrossRef25
Luigi Titomanlio, Annemieke Kavelaars, Jeremie Dalous, Shyamala Mani, Vincent El Ghouzzi, Cobi Heijnen, Olivier Baud, Pierre Gressens. (2011) Stem cell therapy for neonatal brain injury: Perspectives and challenges. Annals of Neurologyn/a-n/a
CrossRef26
Fong CY, Gauthaman K, Cheyyatraivendran S, Lin HD, Biswas A, Bongso A. (2011) Human Umbilical Cord Wharton's Jelly Stem Cells and its Conditioned Medium Support Hematopoietic Stem Cell Expansion Ex Vivo. Journal of Cellular Biochemistryn/a-n/a
CrossRef27
Ryan P. Dorin, Chester J. Koh. 2011. Fetal Tissues. , 819-832.
CrossRef28
Yong-Soo Choi, Sang-Eun Noh, Sang-Min Lim, Dong-il Kim. (2010) Optimization of ex vivo hematopoietic stem cell expansion in intermittent dynamic cultures. Biotechnology Letters 32:12, 1969-1975
CrossRef29
Hitomi TSUJI, Takashi WADA, Masamoto MURAKAMI, Takayuki KASHIWAGI, Yasuhiro ITO, Akemi ISHIDA-YAMAMOTO, Junko JIMBO, Motohiro SHINDO, Kazuya SATO, Yutaka KOHGO, Hajime IIZUKA. (2010) Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. The Journal of Dermatology 37:12, 1040-1045
CrossRef30
A.-L. Herr, N. Kabbara, C. M. S. Bonfim, P. Teira, F. Locatelli, K. Tiedemann, A. Lankester, J.-P. Jouet, C. Messina, Y. Bertrand, C. Diaz de Heredia, C. Peters, W. Chaves, S. K. Nabhan, I. Ionescu, E. Gluckman, V. Rocha. (2010) Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 116:11, 1849-1856
CrossRef31
David A. Jacobsohn. (2010) Optimal management of chronic graft-versus-host disease in children. British Journal of Haematology 150:3, 278-292
CrossRef32
Magali Le Garff-Tavernier, Vivien Béziat, Julie Decocq, Virginie Siguret, Frédérique Gandjbakhch, Eric Pautas, Patrice Debré, Hélène Merle-Beral, Vincent Vieillard. (2010) Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 9:4, 527-535
CrossRef33
Alice Bertaina, Maria Ester Bernardo, Maurizio Caniglia, Luciana Vinti, Giovanna Giorgiani, Franco Locatelli. (2010) Cord blood transplantation in children with haematological malignancies. Best Practice & Research Clinical Haematology 23:2, 189-196
CrossRef34
M. Screnci, E. Murgi, D. Carmini, L. Piro, N. Cinelli, L. Laurenti, A. P. Iori, F. Simone, S. Massari, G. Girelli. (2010) Related cord blood banking for haematopoietic stem cell transplantation. Transfusion Medicine 20:3, 185-190
CrossRef35
Elisabeth T. Tracy, Lindsay J. Talbot, Joanne Kurtzberg, Henry E. Rice. (2010) Splenectomy and partial splenectomy improve hematopoietic stem cell engraftment in hypersplenic mice. Journal of Pediatric Surgery 45:6, 1365-1369
CrossRef36
Annalisa Ruggeri, Fabio Ciceri, Eliane Gluckman, Myriam Labopin, Vanderson Rocha. (2010) Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?. Best Practice & Research Clinical Haematology 23:2, 207-216
CrossRef37
Meghan Delaney, Karen K. Ballen. (2010) The role of HLA in umbilical cord blood transplantation. Best Practice & Research Clinical Haematology 23:2, 179-187
CrossRef38
Edouard I. Azzam, Zhi Yang, Min Li, Soyeon Kim, Olga A. Kovalenko, Manoochehr Khorshidi, Norman Ende. (2010) The effect of human cord blood therapy on the intestinal tract of lethally irradiated mice: Possible use for mass casualties. International Journal of Radiation Biology 86:6, 467-475
CrossRef39
Alexander H. Schmidt, Alexander Platz, Claudia Rutt, Gerhard Ehninger. (2010) Making the Case for Private Cord Blood Banking: Mission Failed!. Stem Cell Reviews and Reports 6:2, 234-236
CrossRef40
Ana Sebrango, Isabel Vicuña, Almudena de Laiglesia, Isabel Millán, Guiomar Bautista, Trinidad Martín-Donaire, Carmen Regidor, Rafael Cabrera, Manuel N. Fernandez. (2010) Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor.. Best Practice & Research Clinical Haematology 23:2, 259-274
CrossRef41
Boglarka Gyurkocza, Andrew Rezvani, Rainer F Storb. (2010) Allogeneic hematopoietic cell transplantation: the state of the art. Expert Review of Hematology 3:3, 285-299
CrossRef42
J.P.R. Motta, B.E. Gomes, L.F. Bouzas, F.H. Paraguassú-Braga, L.C. Porto. (2010) Evaluations of bioantioxidants in cryopreservation of umbilical cord blood using natural cryoprotectants and low concentrations of dimethylsulfoxide
. Cryobiology 60:3, 301-307
CrossRef43
Toshiro Kurokawa, Ken Ishiyama, Jun Ozaki, Yumiko Yamashita, Noriko Iwaki, Chizuru Saito, Masahisa Arahata, Hiroyasu Kaya, Takashi Yoshida. (2010) Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. International Journal of Hematology 91:4, 661-669
CrossRef44
Christian Leeb, Marcin Jurga, Colin McGuckin, Richard Moriggl, Lukas Kenner. (2010) Promising New Sources for Pluripotent Stem Cells. Stem Cell Reviews and Reports 6:1, 15-26
CrossRef45
M. R. Verneris, J. E. Wagner. (2010) UCB and atmospheric noise. Blood 115:4, 754-755
CrossRef46
Michaela Merkerova, Alzbeta Vasikova, Monika Belickova, Hana Bruchova. (2010) MicroRNA Expression Profiles in Umbilical Cord Blood Cell Lineages. Stem Cells and Development 19:1, 17-26
CrossRef47
John E. Wagner, Eliane Gluckman. (2010) Umbilical Cord Blood Transplantation: The First 20 Years. Seminars in Hematology 47:1, 3-12
CrossRef48
Andromachi Scaradavou. (2010) Unrelated Umbilical Cord Blood Unit Selection. Seminars in Hematology 47:1, 13-21
CrossRef49
Vanderson Rocha, Hal E. Broxmeyer. (2010) New Approaches for Improving Engraftment after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 16:1, S126-S132
CrossRef50
DAVID WEEDON, GEOFFREY STRUTTON, ADAM I RUBIN. 2010. The lichenoid reaction pattern (‘interface dermatitis’). , 35-70.
CrossRef51
2010. 3 The lichenoid reaction pattern (‘interface dermatitis’). , 7-48.
CrossRef52
Muhammad A. Mir, Minoo Battiwalla. (2009) Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Mycopathologia 168:6, 271-282
CrossRef53
Rachael Hough, Nicola Cooper, Paul Veys. (2009) Allogeneic haemopoietic stem cell transplantation in children: what alternative donor should we choose when no matched sibling is available?. British Journal of Haematology 147:5, 593-613
CrossRef54
M. Delaney. (2009) Are 2 cords better than 1?. Blood 114:19, 3980-3981
CrossRef55
V Rocha, N Kabbara, I Ionescu, A Ruggeri, D Purtill, E Gluckman. (2009) Pediatric related and unrelated cord blood transplantation for malignant diseases. Bone Marrow Transplantation 44:10, 653-659
CrossRef56
Hans-Jochem Kolb, Belinda Simoes, Christoph Schmid. (2009) Stem cell transplants for patients with relapsed/refractory leukaemia. Current Opinion in Hematology 16:6, 444-452
CrossRef57
E Gluckman. (2009) History of cord blood transplantation. Bone Marrow Transplantation 44:10, 621-626
CrossRef58
V K Prasad, J Kurtzberg. (2009) Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplantation 44:10, 643-651
CrossRef59
C G Brunstein, D J Weisdorf. (2009) Future of cord blood for oncology uses. Bone Marrow Transplantation 44:10, 699-707
CrossRef60
Colleen Delaney, Jonathan A. Gutman, Frederick R. Appelbaum. (2009) Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. British Journal of Haematology 147:2, 207-216
CrossRef61
Cristina Navarrete, Marcela Contreras. (2009) Cord blood banking: a historical perspective. British Journal of Haematology 147:2, 236-245
CrossRef62
Manuel N. Fernández. (2009) Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. British Journal of Haematology 147:2, 161-176
CrossRef63
Vanderson Rocha, Eliane Gluckman, . (2009) Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. British Journal of Haematology 147:2, 262-274
CrossRef64
Eliane Gluckman. (2009) Ten years of cord blood transplantation: from bench to bedside. British Journal of Haematology 147:2, 192-199
CrossRef65
Anjali J. Kaimal, Catherine C. Smith, Russell K. Laros, Aaron B. Caughey, Yvonne W. Cheng. (2009) Cost-effectiveness of Private Umbilical Cord Blood Banking. Obstetrics & Gynecology 114:4, 848-855
CrossRef66
Anfisa Stanevsky, Gal Goldstein, Arnon Nagler. (2009) Umbilical cord blood transplantation: Pros, cons and beyond. Blood Reviews 23:5, 199-204
CrossRef67
Michaela Merkerova, Alzbeta Vasikova, Hana Bruchova, Helena Libalova, Jan Topinka, Ivan Balascak, Radim J. Sram, Radim Brdicka. (2009) Differential gene expression in umbilical cord blood and maternal peripheral blood. European Journal of Haematology 83:3, 183-190
CrossRef68
Xu Shi-xia, Tang Xian-hua, Xu Hai-qin, Feng Bo, Chen Hai-qing, Tang Xiang-Feng. (2009) Meta-analysis of HLA matching and the outcome of unrelated umbilical cord blood transplantation (CBT). Transplant Immunology 21:4, 234-239
CrossRef69
Peter Hollands, Catherina McCauley. (2009) Private Cord Blood Banking: Current Use and Clinical Future. Stem Cell Reviews and Reports 5:3, 195-203
CrossRef70
Tang-Her Jaing, Iou-Jih Hung, Chao-Ping Yang, Ming-Horng Tsai, Wen-I Lee, Chien-Feng Sun. (2009) Second transplant with two unrelated cord blood units for early graft failure after cord blood transplantation for thalassemia. Pediatric Transplantation 13:6, 766-768
CrossRef71
B E Shaw, P Veys, A Pagliuca, J Addada, G Cook, C F Craddock, A R Gennery, J Goldman, S Mackinnon, J A Madrigal, D I Marks, C Navarrete, M N Potter, S Querol, F Regan, N H Russell, R E Hough. (2009) Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplantation 44:1, 7-12
CrossRef72
Syh-Jae Lin, Chen-Cheng Lee, Po-Jen Cheng, Lai-Chu See, Ming-Ling Kuo. (2009) Susceptibility to Fas and tumor necrosis factor-α receptor mediated apoptosis of anti-CD3/anti-CD28-activated umbilical cord blood T cells. Pediatric Allergy and Immunology 20:4, 392-398
CrossRef73
Bahman Delalat, Ali Akbar Pourfathollah, Masoud Soleimani, Hossein Mozdarani, Soraya Rasi Ghaemi, Ali Akbar Movassaghpour, Saeed Kaviani. (2009) Isolation and <I>ex vivo</I> expansion of human umbilical cord blood-derived CD34<SUP>+</SUP> stem cells and their cotransplantation with or without mesenchymal stem cells. Hematology 14:3, 125-132
CrossRef74
Xavier Bérard, Murielle Rémy-Zolghadri, Chantal Bourget, Neill Turner, Reine Bareille, Richard Daculsi, Laurence Bordenave. (2009) Capability of human umbilical cord blood progenitor-derived endothelial cells to form an efficient lining on a polyester vascular graft in vitro. Acta Biomaterialia 5:4, 1147-1157
CrossRef75
Xu Shi-xia, Tang Xian-hua, Tang Xiang-feng. (2009) Unrelated umbilical cord blood transplantation and unrelated bone marrow transplantation in children with hematological disease: A meta-analysis. Pediatric Transplantation 13:3, 278-284
CrossRef76
Eva C. Guinan. (2009) Acquired Aplastic Anemia in Childhood. Hematology/Oncology Clinics of North America 23:2, 171-191
CrossRef77
Paul J Martin. (2009) Choosing between GVHD and delayed engraftment. Nature Medicine 15:4, 363-364
CrossRef78
S A Boxall, G P Cook, D Pearce, D Bonnet, Y M El-Sherbiny, M P Blundell, S J Howe, J P Leek, A F Markham, E A de Wynter. (2009) Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells. Bone Marrow Transplantation 43:8, 627-635
CrossRef79
Nadereh Naderi, Ali Akbar Pourfathollah, Kamran Alimoghaddam, Seyed Mohammad Moazzeni. (2009) Cord blood dendritic cells prevent the differentiation of naïve T-helper cells towards Th1 irrespective of their subtype. Clinical and Experimental Medicine 9:1, 29-36
CrossRef80
M Battiwalla, P L McCarthy. (2009) Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplantation 43:5, 351-356
CrossRef81
G Bautista, J R Cabrera, C Regidor, R Forés, J A García-Marco, E Ojeda, I Sanjuán, E Ruiz, I Krsnik, B Navarro, S Gil, E Magro, A de Laiglesia, R Gonzalo-Daganzo, T Martín-Donaire, M Rico, I Millán, M N Fernández. (2009) Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplantation 43:5, 365-373
CrossRef82
Y. Atsuta, R. Suzuki, T. Nagamura-Inoue, S. Taniguchi, S. Takahashi, S. Kai, H. Sakamaki, Y. Kouzai, M. Kasai, T. Fukuda, H. Azuma, M. Takanashi, S. Okamoto, M. Tsuchida, K. Kawa, Y. Morishima, Y. Kodera, S. Kato, . (2009) Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 113:8, 1631-1638
CrossRef83
T E Petterson, M Gabriel, K Tiedemann, L Teague, P J Shaw, D Baker, R Bolton-Jones, H Tapp, C Oswald, M R Vowels, T A O'Brien. (2009) Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. Bone Marrow Transplantation 43:3, 207-215
CrossRef84
B-S Cho, C-K Min, K-S Eom, Y-J Kim, H-J Kim, S Lee, S-G Cho, D-W Kim, J-W Lee, W-S Min, C-C Kim. (2009) Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 23:1, 78-84
CrossRef85
Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn. (2009) Recent advance in primary immune deficiency disorders. Korean Journal of Pediatrics 52:6, 649
CrossRef86
Hye Ryun Lee, Sue Shin, Jong Hyun Yoon, Byoung Jae Kim, Kyu Ri Hwang, Jin Ju Kim, Eun Youn Roh. (2009) Complete Blood Count Reference Values of Donated Cord Blood from Korean Neonates. The Korean Journal of Laboratory Medicine 29:3, 179
CrossRef87
Mi Sun Ahn, Young-woo Eom, Joon Seong Park, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Mal Sook Yang, Hyo Eun Kim, In Keun Jang, Jong Eun Lee, Young Jin Kim, Hugh Chul Kim, Seong Hyun Jeong. (2009) Difference in Viability of CD34+ Cells in Cryopreserved Cord Blood According to Evaluation Methods. The Korean Journal of Hematology 44:2, 92
CrossRef88
Priya Kumar, Todd E. Defor, Claudio Brunstein, Juliet N. Barker, John E. Wagner, Daniel J. Weisdorf, Linda J. Burns. (2008) Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival. Biology of Blood and Marrow Transplantation 14:12, 1394-1400
CrossRef89
Takuya Fukushima, Kensuke Horio, Emi Matsuo, Daisuke Imanishi, Reishi Yamasaki, Hideki Tsushima, Yoshitaka Imaizumi, Koichi Ohshima, Tomoko Hata, Shinichiro Yoshida, Yasushi Miyazaki, Masao Tomonaga. (2008) Successful cord blood transplantation for mycosis fungoides. International Journal of Hematology 88:5, 596-598
CrossRef90
L M Ball, M E Bernardo, F Locatelli, R M Egeler. (2008) Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow Transplantation 42, S60-S66
CrossRef91
Larry Denner, Randall J Urban. (2008) Critical issues for engineering cord blood stem cells to produce insulin. Expert Opinion on Biological Therapy 8:9, 1251-1254
CrossRef92
Navneet S. Majhail, Claudio G. Brunstein, Sarah McAvoy, Todd E. DeFor, Ahmed Al-Hazzouri, Daniela Setubal, Mukta Arora, Chap T. Le, John E. Wagner, Daniel J. Weisdorf. (2008) Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical Cord Blood and Matched Related Donor Transplants. Biology of Blood and Marrow Transplantation 14:9, 985-992
CrossRef93
L-P Koh, N Chao. (2008) Haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation 42, S60-S63
CrossRef94
Michael J. Sullivan. (2008) Banking on cord blood stem cells. Nature Reviews Cancer 8:7, 555-563
CrossRef95
William Tse, Kevin D Bunting, Mary J Laughlin. (2008) New insights into cord blood stem cell transplantation. Current Opinion in Hematology 15:4, 279-284
CrossRef96
Marcelo C. Pasquini. (2008) Impact of graft-versus-host disease on survival. Best Practice & Research Clinical Haematology 21:2, 193-204
CrossRef97
C Messina, M Faraci, V de Fazio, G Dini, M P Calò, E Calore. (2008) Prevention and treatment of acute GvHD. Bone Marrow Transplantation 41, S65-S70
CrossRef98
Julia A. Brown, Vassiliki A. Boussiotis. (2008) Umbilical cord blood transplantation: Basic biology and clinical challenges to immune reconstitution. Clinical Immunology 127:3, 286-297
CrossRef99
F Locatelli, G Giorgiani, A Di-Cesare-Merlone, P Merli, V Sparta, F Moretta. (2008) The changing role of stem cell transplantation in childhood. Bone Marrow Transplantation 41, S3-S7
CrossRef100
K Sugimoto, H Narimatsu, T Kawase, H Iida, M Watanabe, A Kohno, Y Kuwatsuka, T Uchida, M Hamaguchi, S Terakura, T Naoe, K Matsuo, M Murata, M Sawa, K Miyamura, Y Morishita. (2008) Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. Bone Marrow Transplantation 41:8, 729-736
CrossRef101
W W Tse, S L Zang, K D Bunting, M J Laughlin. (2008) Umbilical cord blood transplantation in adult myeloid leukemia. Bone Marrow Transplantation 41:5, 465-472
CrossRef102
Navneet S. Majhail, Claudio G. Brunstein, Marcie Tomblyn, Avis J. Thomas, Jeffrey S. Miller, Mukta Arora, Dan S. Kaufman, Linda J. Burns, Arne Slungaard, Philip B. McGlave, John E. Wagner, Daniel J. Weisdorf. (2008) Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. Biology of Blood and Marrow Transplantation 14:3, 282-289
CrossRef103
Fernando O. Pinto, Irene Roberts. (2008) Cord blood stem cell transplantation for haemoglobinopathies. British Journal of Haematology 0:0, 080226145103436-???
CrossRef104
Andrew R Rezvani, Rainer Storb. (2008) Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opinion on Biological Therapy 8:2, 161-179
CrossRef105
C. P. McGuckin, N. Forraz. (2008) Potential for access to embryonic-like cells from human umbilical cord blood. Cell Proliferation 41, 31-40
CrossRef106
M Bhatia, M C Walters. (2008) Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplantation 41:2, 109-117
CrossRef107
Syh-Jae Lin, Dah-Chin Yan, Yen-Chang Lee, Ming-Ling Kuo. (2008) Role of Interleukin-15 in Umbilical Cord Blood Transplantation. International Reviews of Immunology 27:6, 518-531
CrossRef108
Ji-Soo KIM, Hyun-Kyung LEE, Mi-Ryung KIM, Pan-Kyeom KIM, Chan-Wha KIM. (2008) Differentially Expressed Proteins of Mesenchymal Stem Cells Derived from Human Cord Blood (hUCB) during Osteogenic Differentiation. Bioscience, Biotechnology, and Biochemistry 72:9, 2309-2317
CrossRef109
Liang-Piu Koh, Nelson J. Chao. (2008) Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: A review. Blood Cells, Molecules, and Diseases 40:1, 20-24
CrossRef110
Carmella van de Ven, Daniel Collins, M. Brigid Bradley, Erin Morris, Mitchell S. Cairo. (2007) The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Experimental Hematology 35:12, 1753-1765
CrossRef111
Carolyn Troeger, Irene Hösli, Wolfgang Holzgreve. (2007) Cord blood for allogeneic and autologous banking. European Clinics in Obstetrics and Gynaecology 3:2, 81-87
CrossRef112
Baris Kuskonmaz, Safak Gocer, Sibel Ersoy-Ewans, Fatma Cetin Ozman, Mualla Cetin, Duygu Uckan. (2007) Hyperacute graft-vs.-host disease after related HLA-identical umbilical cord blood transplantation. Pediatric Transplantation 11:7, 818-820
CrossRef113
Syh-Jae Lin, Ming-Ling Kuo, Po-Jen Cheng, Shiu-Shan Hsiao. (2007) Differential cyclosporin-A sensitivity on survival and activation of umbilical cord and adult peripheral blood CD4+ T cells. Transplant Immunology 18:2, 172-178
CrossRef114
Liang-Piu Koh, David A. Rizzieri, Nelson J. Chao. (2007) Allogeneic Hematopoietic Stem Cell Transplant Using Mismatched/Haploidentical Donors. Biology of Blood and Marrow Transplantation 13:11, 1249-1267
CrossRef115
Willem J. Van Heeckeren, Laura R. Fanning, Howard J. Meyerson, Pingfu Fu, Hillard M. Lazarus, Brenda W. Cooper, William W. Tse, Tamila L. Kindwall-Keller, Jennifer Jaroscak, Marcie R. Finney, Robert M. Fox, Luis Solchaga, Margaret Forster, Richard J. Creger, Mary J. Laughlin. (2007) Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. British Journal of Haematology 139:3, 464-474
CrossRef116
M B Bradley, P Satwani, L Baldinger, E Morris, C van de Ven, G Del Toro, J Garvin, D George, M Bhatia, E Roman, L A Baxter-Lowe, J Schwartz, E Qualter, R Hawks, K Wolownik, S Foley, O Militano, J Leclere, Y-K Cheung, M S Cairo. (2007) Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplantation 40:7, 621-631
CrossRef117
Eliane Gluckman, Vanderson Rocha, Irina Ionescu, Marc Bierings, Richard E. Harris, John Wagner, Joanne Kurtzberg, Martin A. Champagne, Carmem Bonfim, Marco Bittencourt, Philip Darbyshire, Manuél-Nicolas Fernandez, Franco Locatelli, Ricardo Pasquini. (2007) Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival. Biology of Blood and Marrow Transplantation 13:9, 1073-1082
CrossRef118
Takayuki Azuma, Yuji Miura, Eiji Kusumi, Masahiro Kami, Tsunehiko Komatsu. (2007) Fatal Pulmonary Hemorrhage Associated With Early Immune Reaction After Reduced Intensity Stem Cell Transplantation. Transplantation 84:5, 667-668
CrossRef119
Jon Smythe, Sue Armitage, Dorothy McDonald, Derwood Pamphilon, Martin Guttridge, Juliette Brown, Ann Green, Colin Brown, Ruth M. Warwick, Alan Lankester, Deirdre Fehily, Marcela Contreras, Cristina Navarrete, Suzanne M. Watt. (2007) Directed Sibling Cord Blood Banking for Transplantation: The 10-Year Experience in the National Blood Service in England. Stem Cells 25:8, 2087-2093
CrossRef120
Alvaro Urbano-Ispizua. (2007) Risk assessment in haematopoietic stem cell transplantation: Stem cell source. Best Practice & Research Clinical Haematology 20:2, 265-280
CrossRef121
Gabrielle N. Samuel, Ian H. Kerridge. (2007) Equity, Utility, and the Marketplace: Emerging Ethical Issues of Umbilical Cord Blood Banking in Australia. Journal of Bioethical Inquiry 4:1, 57-63
CrossRef122
Joong-Pyo Kim, Young-Ho Lee, Young-Ah Lee, Young-Dae Kim. (2007) A Comparison of the Kinetics of Nucleated Cells and CD34+ Cells in Neonatal Peripheral Blood and Cord Blood. Biology of Blood and Marrow Transplantation 13:4, 478-485
CrossRef123
Andrea Bacigalupo. (2007) Management of acute graft-versus-host disease. British Journal of Haematology 137:2, 87-98
CrossRef124
William Ying Khee Hwang, Miny Samuel, Daryl Tan, Liang Piu Koh, Winston Lim, Yeh Ching Linn. (2007) A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation 13:4, 444-453
CrossRef125
A Takami, M Shibayama, M Orito, M Omote, H Okumura, T Yamashita, S Shimadoi, T Yoshida, S Nakao, H Asakura. (2007) Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplantation 39:8, 501-507
CrossRef126
Lisbeth A. Welniak, Bruce R. Blazar, William J. Murphy. (2007) Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. Annual Review of Immunology 25:1, 139-170
CrossRef127
C Lemarie, B Esterni, B Calmels, B Dazey, V Lapierre, L Lecchi, A Meyer, D Rea, I Thuret, H Chambost, C Curtillet, C Chabannon, G Michel. (2007) CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation. Bone Marrow Transplantation 39:8, 453-460
CrossRef128
Viviane A. Nunes, Natale Cavaçana, Martha Canovas, Bryan E. Strauss, Mayana Zatz. (2007) Stem cells from umbilical cord blood differentiate into myotubes and express dystrophin in vitro only after exposure to in vivo muscle environment. Biology of the Cell 99:4, 185
CrossRef129
Araceli Encabo, Pilar Solves, Francisco Carbonell-Uberos, Maria Dolores Miñana. (2007) The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation. Transfusion 47:2, 272-279
CrossRef130
Jeffrey K. Davies, Eva C. Guinan. (2007) An update on the management of severe idiopathic aplastic anaemia in children. British Journal of Haematology 136:4, 549-564
CrossRef131
Claudia R Morris, Sylvia T Singer, Mark C Walters. (2007) Clinical hemoglobinopathies: iron, lungs and new blood. Current Opinion in Internal Medicine 6:1, 60-71
CrossRef132
Erik J. Woods, Karen E. Pollok, Michael A. Byers, Brandon C. Perry, Jester Purtteman, Shelly Heimfeld, Dayong Gao. (2007) Cord Blood Stem Cell Cryopreservation. Transfusion Medicine and Hemotherapy 34:4, 276-285
CrossRef133
Young-Ho Lee. (2007) Cord Blood - Current Status and Perspective. The Korean Journal of Hematology 42:3, 181
CrossRef134
F.M. Kloosterboer, S.A.P. van Luxemburg-Heijs, R. Willemze, J.H.F. Falkenburg. (2006) Similar Potential to Become Activated and Proliferate but Differential Kinetics and Profiles of Cytokine Production of Umbilical Cord Blood T Cells and Adult Blood Naive and Memory T Cells. Human Immunology 67:11, 874-883
CrossRef135
N Qureshi, B Lubin, M C Walters. (2006) The prevention and management of stroke in sickle cell anaemia. Expert Opinion on Biological Therapy 6:11, 1087-1098
CrossRef136
Gerard Madlambayan, Ian Rogers. (2006) Umbilical cord-derived stem cells for tissue therapy: current and future uses. Regenerative Medicine 1:6, 777-787
CrossRef137
Eliane Gluckman. (2006) Transplantation. Current Opinion in Immunology 18:5, 556-558
CrossRef138
Eliane Gluckman, Vanderson Rocha. (2006) Donor selection for unrelated cord blood transplants. Current Opinion in Immunology 18:5, 565-570
CrossRef139
Claudio G. Brunstein, John E. Wagner. (2006) Cord blood transplantation for adults. Vox Sanguinis 91:3, 195-205
CrossRef140
Jae-Seung Shim, Bin Cho, Myungshin Kim, Gyeong-Sin Park, Jong-Chul Shin, Hong-Kyu Hwang, Tae-Gyu Kim, Il-Hoan Oh. (2006) Early apoptosis in CD34 + cells as a potential heterogeneity in quality of cryopreserved umbilical cord blood. British Journal of Haematology 135:2, 210-213
CrossRef141
Robertson Parkman, Geoff Cohen, Shelly L. Carter, Kenneth I. Weinberg, Bernadette Masinsin, Eva Guinan, Joanne Kurtzberg, John E. Wagner, Nancy A. Kernan. (2006) Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 12:9, 919-927
CrossRef142
Raffaele Renella, Capucine Picard, Benedicte Neven, Marie Ouachee-Chardin, Jean-Laurent Casanova, Francoise Le Deist, Marina Cavazzana-Calvo, Stephane Blanche, Alain Fischer. (2006) Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections. British Journal of Haematology 134:5, 510-516
CrossRef143
William Arcese, Alessandra Picardi, Raffaella Cerretti, Laura Cudillo, Gottardo De Angelis, Luca Franceschini, Lidia De Felice, Massimiliano Postorino. (2006) The Therapeutic Use of Cord Blood. Cell Preservation Technology 4:3, 161-168
CrossRef144
Demetrios Petropoulos, Ka Wah Chan. (2006) Umbilical cord blood transplantation. Current Hematologic Malignancy Reports 1:3, 197-200
CrossRef145
Yue Zhang, Chou Chai, Xue-Song Jiang, Swee-Hin Teoh, Kam W. Leong. (2006) Co-culture of Umbilical Cord Blood CD34 + Cells with Human Mesenchymal Stem Cells. Tissue Engineering 0:0, 060913044658049
CrossRef146
Yue Zhang, Chou Chai, Xue-Song Jiang, Swee-Hin Teoh, Kam W. Leong. (2006) Co-culture of Umbilical Cord Blood CD34þ Cells with Human Mesenchymal Stem Cells. Tissue Engineering 12:8, 2161-2170
CrossRef147
Eliane Gluckman. (2006) Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 12:8, 808-812
CrossRef148
Syh-Jae Lin, Po-Jen Cheng, Dah-Chin Yan, Pei-Tzu Lee, Hsiu-Shan Hsaio. (2006) Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transplant Immunology 16:2, 112-116
CrossRef149
Andrea Finocchi, Maria Luisa Romiti, Silvia Di Cesare, Pamela Puliafito, Simone Pensieroso, Ippolita Rana, Rita Pinto, Caterina Cancrini, Giulio De Rossi, Maurizio Caniglia, Paolo Rossi. (2006) Rapid T-cell Receptor CD4+ Repertoire Reconstitution and Immune Recovery in Unrelated Umbilical Cord Blood Transplanted Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology 28:7, 403-411
CrossRef150
M A Slatter, A R Gennery. (2006) Umbilical cord stem cell transplantation for primary immunodeficiencies. Expert Opinion on Biological Therapy 6:6, 555-565
CrossRef151
Xiao N Wang, Anne M Dickinson. (2006) The 6th Annual Meeting of the UK Cord Blood and Adult Stem Cell Group. Expert Opinion on Biological Therapy 6:4, 417-421
CrossRef152
Taina Jaatinen, Heidi Hemmoranta, Sampsa Hautaniemi, Jari Niemi, Daniel Nicorici, Jarmo Laine, Olli Yli-Harja, Jukka Partanen. (2006) Global Gene Expression Profile of Human Cord Blood-Derived CD133 + Cells. Stem Cells 24:3, 631-641
CrossRef153
William Tse, Kevin D Bunting, Mary J Laughlin. (2006) Umbilical cord blood transplantation: an alternative for adult patients. Current Opinion in Organ Transplantation 11:1, 37-45
CrossRef154
Claudio G. Brunstein, John E. Wagner. (2006) Umbilical Cord Blood Transplantation and Banking. Annual Review of Medicine 57:1, 403-417
CrossRef155
Lei Zhang, Renchi Yang, Zhong Chao Han. (2006) Transplantation of umbilical cord blood-derived endothelial progenitor cells: a promising method of therapeutic revascularisation. European Journal of Haematology 76:1, 1-8
CrossRef156
Chih-Chao Chang, Prakash Satwani, Nora Oberfield, George Vlad, Lynn L. Simpson, Mitchell S. Cairo. (2005) Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: A comparative study of naïve and antigenic-specific cord blood Treg cells. Experimental Hematology 33:12, 1508-1520
CrossRef157
Alexandra H. Filipovich, Daniel Weisdorf, Steven Pavletic, Gerard Socie, John R. Wingard, Stephanie J. Lee, Paul Martin, Jason Chien, Donna Przepiorka, Daniel Couriel, Edward W. Cowen, Patricia Dinndorf, Ann Farrell, Robert Hartzman, Jean Henslee-Downey, David Jacobsohn, George McDonald, Barbara Mittleman, J. Douglas Rizzo, Michael Robinson, Mark Schubert, Kirk Schultz, Howard Shulman, Maria Turner, Georgia Vogelsang, Mary E.D. Flowers. (2005) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation 11:12, 945-956
CrossRef158
Demetrios Petropoulos, Ka Wah Chan. (2005) Umbilical cord blood transplantation. Current Oncology Reports 7:6, 406-409
CrossRef159
Kelly K. Sawczyn, Ralph Quinones, Janet Malcolm, Nicholas Foreman, Tim Garrington, Lia Gore, Dexiang Gao, Roger Giller. (2005) Cord blood transplant in childhood ALL. Pediatric Blood & Cancer 45:7, 964-970
CrossRef160
Thomas O. Kleen, Suzanne Kadereit, Laura R. Fanning, Jennifer Jaroscak, Pingfu Fu, Howard J. Meyerson, Lara Kulchycki, Laura F. Slivka, Margaret Kozik, Magdalena Tary-Lehmann, Mary J. Laughlin. (2005) Recipient-Specific Tolerance after HLA-Mismatched Umbilical Cord Blood Stem Cell Transplantation. Transplantation 80:9, 1316-1322
CrossRef161
Alma J. Nauta, Alwine B. Kruisselbrink, Ellie Lurvink, Arend Mulder, Frans H. Claas, Willy A. Noort, Roel Willemze, Willem E. Fibbe. (2005) Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit. Experimental Hematology 33:10, 1249-1256
CrossRef162
Jordan H. Perlow. (2005) The Case Against Private Umbilical Cord Blood Banking. Obstetrics & Gynecology 106:4, 865-866
CrossRef163
Syh-Jae Lin, Po-Jen Cheng, Shiu-Shan Hsiao, Hui-Hao Lin, Pei-Fen Hung, Ming-Ling Kuo. (2005) Differential effect of IL-15 and IL-2 on survival of phytohemagglutinin-activated umbilical cord blood T cells. American Journal of Hematology 80:2, 106-112
CrossRef164
C. Troeger, D. V. Surbek, W. Holzgreve. (2005) Stammzellen aus Nabelschnurblut. Der Gynäkologe 38:9, 829-837
CrossRef165
Prakash Satwani, Janet Ayello, Carmella Ven, Allison F. O'Neill, Lynn L. Simpson, Laxmi Baxi, Mitchell S. Cairo. (2005) Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function*. British Journal of Haematology 130:2, 284-292
CrossRef166
Yukiko Kishi, Masahiro Kami, Shigesaburo Miyakoshi, Yoshinobu Kanda, Naoko Murashige, Takanori Teshima, Eiji Kusumi, Shigeo Hara, Tomoko Matsumura, Koichiro Yuji, Kazuhiro Masuoka, Atsushi Wake, Shinichi Morinaga, Mineo Kanemaru, Tatsuyuki Hayashi, Yuji Tanaka, Shuichi Taniguchi. (2005) Early Immune Reaction after Reduced-Intensity Cord-Blood Transplantation for Adult Patients. Transplantation 80:1, 34-40
CrossRef167
Joanne Kurtzberg, Mitchell S. Cairo, John K. Fraser, LeeAnn Baxter-Lowe, Geoff Cohen, Shelly L. Carter, Nancy A. Kernan. (2005) Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. Transfusion 45:6, 842-855
CrossRef168
M. Brigid Bradley, Mitchell S. Cairo. (2005) Cord Blood Immunology and Stem Cell Transplantation. Human Immunology 66:5, 431-446
CrossRef169
JEAN-HUGUES DALLE, JOS?? MENEZES, ??RIC WAGNER, MARIE BLAGDON, JOSETTE CHAMPAGNE, MARTIN A. CHAMPAGNE, MICHEL DUVAL. (2005) Characterization of Cord Blood Natural Killer Cells: Implications for Transplantation and Neonatal Infections. Pediatric Research 57:5 Part 1, 649-655
CrossRef170
Masoud Soleimani ., Hossein Mozdarani ., AliAkbar Pourfathollah ., Yousef Mortazavi ., Kamran Alimoghaddam ., Mahin Nikogoftar ., Zahra Zonobi ., Abbas Hajifathali .. (2005) A Co-culture System for Expansion of Nonenriched Cord Blood Stem/Progenitor Cells. Biotechnology(Faisalabad) 4:4, 310-315
CrossRef171
Eliane Gluckman, Gesine Koegler, Vanderson Rocha. (2005) Human leukocyte antigen matching in cord blood transplantation. Seminars in Hematology 42:2, 85-90
CrossRef172
Sabeen Askari, John Miller, Gayl Chrysler, Jeffrey McCullough. (2005) Impact of donor- and collection-related variables on product quality in ex utero cord blood banking. Transfusion 45:2, 189-194
CrossRef173
Arnon Nagler. 2005. Stem Cell Transplantation. .
CrossRef174
E Gluckman, V Rocha. (2005) History of the clinical use of umbilical cord blood hematopoietic cells. Cytotherapy 7:3, 219-227
CrossRef175
Nicholas M. Fisk, Irene A. G. Roberts, Roger Markwald, Vladimir Mironov. (2005) Can Routine Commercial Cord Blood Banking Be Scientifically and Ethically Justified?. PLoS Medicine 2:2, e44
CrossRef176
P Flores-Guzmán, E Flores-Figueroa, G Martínez-Jaramillo, H Mayani. (2005) In vitro characterization of two lineage-negative CD34 + cell-enriched hematopoietic cell populations from human UC blood. Cytotherapy 7:4, 334-344
CrossRef177
W Tse, MJ Laughlin. (2005) Cord blood transplantation in adult patients. Cytotherapy 7:3, 228-242
CrossRef178
M. BOFILL, E. ALMIRALL, A. MCQUAID, R. PENA, R. RUIZ-HERNANDEZ, M. NARANJO, L. RUIZ, B. CLOTET, F. E. BORRAS. (2004) Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA+ and CD45RO+ phenotype from tonsils, cord and adult peripheral blood. Clinical and Experimental Immunology 138:3, 460-465
CrossRef179
Rodrigo A. Panepucci, Jorge L.C. Siufi, Wilson A. Silva, Rodrigo Proto-Siquiera, Luciano Neder, Maristela Orellana, Vanderson Rocha, Dimas T. Covas, Marco A. Zago. (2004) Comparison of Gene Expression of Umbilical Cord Vein and Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells 22:7, 1263-1278
CrossRef180
Rocha, Vanderson, Labopin, Myriam, Sanz, Guillermo, Arcese, William, Schwerdtfeger, Rainer, Bosi, Alberto, Jacobsen, Niels, Ruutu, Tapani, de Lima, Marcos, Finke, Jürgen, Frassoni, Francesco, Gluckman, Eliane, . (2004) Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. New England Journal of Medicine 351:22, 2276-2285
Full Text181
Laughlin, Mary J., Eapen, Mary, Rubinstein, Pablo, Wagner, John E., Zhang, Mei-Jei, Champlin, Richard E., Stevens, Cladd, Barker, Juliet N., Gale, Robert P., Lazarus, Hillard M., Marks, David I., van Rood, Jon J., Scaradavou, Andromachi, Horowitz, Mary M., . (2004) Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. New England Journal of Medicine 351:22, 2265-2275
Full Text182
Loren E. Wold, Wangde Dai, Casilde Sesti, Sharon L. Hale, Joan S. Dow, Bradley J. Martin, Robert A. Kloner. (2004) Stem Cell Therapy for the Heart. Congestive Heart Failure 10:6, 293-301
CrossRef183
Vanderson Rocha, Guillermo Sanz, Eliane Gluckman. (2004) Umbilical cord blood transplantation. Current Opinion in Hematology 11:6, 375-385
CrossRef184
P Aroviita, K Teramo, V Hiilesmaa, P Westman, R Kekomäki. (2004) Birthweight of full-term infants is associated with cord blood CD34+ cell concentration. Acta Paediatrica 93:10, 1323-1329
CrossRef185
Yossi Cohen, Arnon Nagler. (2004) Umbilical cord blood transplantation – how, when and for whom?. Blood Reviews 18:3, 167-179
CrossRef186
Carl van Walraven, Darryl Davis, Alan J. Forster, George A. Wells. (2004) Time-dependent bias was common in survival analyses published in leading clinical journals. Journal of Clinical Epidemiology 57:7, 672-682
CrossRef187
Jennifer G. Hall, Paul L. Martin, Susan Wood, Joanne Kurtzberg. (2004) Unrelated Umbilical Cord Blood Transplantation for an Infant With ??-Thalassemia Major. Journal of Pediatric Hematology/Oncology 26:6, 382-385
CrossRef188
Sue Davey, Sue Armitage, Vanderson Rocha, Federico Garnier, Juliette Brown, Colin J. Brown, Ruth Warwick, Deidre Fehily, Suzanne Watt, Eliane Gluckman, Ajay Vora, Marcela Contreras, Cristina V. Navarrete. (2004) The London Cord Blood Bank: analysis of banking and transplantation outcome. British Journal of Haematology 125:3, 358-365
CrossRef189
Eliane Gluckman. (2004) Ex vivo expansion of cord blood cells. Experimental Hematology 32:5, 410-412
CrossRef190
Eliane Gluckman, Vanderson Rocha, William Arcese, Gérard Michel, Guillermo Sanz, Ka-Wah Chan, Tsuneo A Takahashi, Juan Ortega, Alexandra Filipovich, Franco Locatelli, Shigetaka Asano, Franca Fagioli, Marcus Vowels, Anne Sirvent, Jean-Philippe Laporte, Karin Tiedemann, Sergio Amadori, Manuel Abecassis, Pierre Bordigoni, Blanca Diez, Peter J Shaw, Ajay Vora, Maurizio Caniglia, Federico Garnier, Irina Ionescu, Joan Garcia, Gesine Koegler, Paolo Rebulla, Sylvie Chevret, on behalf of the Eurocord Group. (2004) Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Experimental Hematology 32:4, 397-407
CrossRef191
Inge Van haute, Nele Lootens, Saskia De Smet, Carine De Buck, Linda Verdegem, Katrien Vanheusden, Jef Pinxteren, Bart Vandekerckhove. (2004) Viable CD34+ stem cell content of a cord blood graft: which measurement performed before transplantation is most representative?. Transfusion 44:4, 547-554
CrossRef192
Yingsong Xiang, Suping Sun, Jianming Cai, Mingfeng Xiang, Gusheng Tang, Xuetao Cao. (2004) ENHANCEMENT OF FRACTIONATED BONE MARROW TRANSPLANTATION ON HEMATOPOIETIC CELL HOMING IN A MOUSE ALLOGENEIC MODEL1. Transplantation 77:7, 972-978
CrossRef193
F.M Kloosterboer, S.A.P.van Luxemburg-Heijs, R Willemze, J.H.F Falkenburg. (2004) Umbilical cord blood–naive T cells but not adult blood–naive T cells require HLA class II on antigen-presenting cells for allo-immune activation. Human Immunology 65:4, 328-339
CrossRef194
Franco Locatelli, Piero De Stefano. (2004) New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. British Journal of Haematology 125:1, 3-11
CrossRef195
John P. Chute, Garrett Muramoto, Jennifer Fung, Carol Oxford. (2004) Quantitative Analysis Demonstrates Expansion of SCID-Repopulating Cells and Increased Engraftment Capacity in Human Cord Blood Following Ex Vivo Culture with Human Brain Endothelial Cells. Stem Cells 22:2, 202-215
CrossRef196
Jianpei Fang, Shaoliang Huang, Chun Chen, Dunhua Zhou, Chi-Kong Li, Yang Li, Ke Huang. (2004) Umbilical Cord Blood Transplantation in Chinese Children With Beta-Thalassemia. Journal of Pediatric Hematology/Oncology 26:3, 185-189
CrossRef197
Ryuji Nakagawa, Tsutomu Watanabe, Yoshifumi Kawano, Sachiyo Kanai, Hiroko Suzuya, Michiya Kaneko, Hiroyoshi Watanabe, Yasuhiro Okamoto, Yasuhiro Kuroda, Takayoshi Nakayama, . (2004) Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. Transfusion 44:2, 262-267
CrossRef198
Michael Boyiadzis, Steven Pavletic. (2004) Haematopoietic stem cell transplantation: indications, clinical developments and future directions. Expert Opinion on Pharmacotherapy 5:1, 97-108
CrossRef199
Hyun Ok Kim. (2004) Use of Cord Blood Stem Cells in Cell Therapy. Journal of the Korean Medical Association 47:10, 957
CrossRef200
Liang-Piu Koh, Nelson J Chao. (2004) Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biology of Blood and Marrow Transplantation 10:1, 1-22
CrossRef201
Young-Ho Lee, Young-Ah Lee, Kyu-Tae Noh, Kyeong-Hee Kim, Jin-Yeong Han, Su-Yeong Seo, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim. (2004) Homing-Associated Cell Adhesion Molecules and Cell Cycle Status on the Nucleated Cells in the Bone Marrow, Mobilized Peripheral Blood and Cord Blood. Journal of Korean Medical Science 19:4, 523
CrossRef202
Young-Ho Lee, Jin-Yeong Han, Su-Yeong Seo, Kyeong-Hee Kim, Young-Ah Lee, Young-Seok Lee, Hyung-Sik Lee, Won-Joo Hur, Hun Han, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim. (2004) Stem Cells Expressing Homing Receptors Could be Expanded From Cryopreserved and Unselected Cord Blood. Journal of Korean Medical Science 19:5, 635
CrossRef203
D.C Kilpatrick, I Downing, J.B Palmer, M.L Turner. (2004) Comparison of adult and fetal cytokine secretion during mixed lymphocyte reactions. Immunology Letters 91:1, 55-61
CrossRef204
Syh-Jae Lin, Jung-Chuan Yu, Po-Jen Cheng, Shiu-Shan Hsiao, Ming-Ling Kuo. (2003) Effect of interleukin-15 on anti-CD3/anti-CD28 induced apoptosis of umbilical cord blood CD4+ T cells. European Journal of Haematology 71:6, 425-432
CrossRef205
Alan S Wayne, A.J Barrett. (2003) Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. Hematology/Oncology Clinics of North America 17:5, 1243-1260
CrossRef206
Tokiko Nagamura-Inoue, Mika Shioya, Michiko Sugo, Yan Cui, Atsuko Takahashi, Satomi Tomita, Yizhou Zheng, Kei Takada, Hideki Kodo, Shigetaka Asano, Tsuneo A. Takahashi. (2003) Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank. Transfusion 43:9, 1285-1295
CrossRef207
Mark Pines, David Snyder, Shai Yarkoni, Arnon Nagler. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biology of Blood and Marrow Transplantation 9:7, 417-425
CrossRef208
U. Aufderhaar, W. Holzgreve, E. Danzer, A. Tichelli, C. Troeger, D. V. Surbek. (2003) The impact of intrapartum factors on umbilical cord blood stem cell banking. Journal of Perinatal Medicine 31:4, 317-322
CrossRef209
Juliet N. Barker, John E. Wagner. (2003) Umbilical-cord blood transplantation for the treatment of cancer. Nature Reviews Cancer 3:7, 526-532
CrossRef210
C.K. Hurley, M. Fernandez Vina, M. Setterholm. (2003) Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens 61:6, 415-424
CrossRef211
Manuel N Fernández, Carmen Regidor, Rafael Cabrera, José A Garcı́a-Marco, Rafael Forés, Isabel Sanjuán, Jorge Gayoso, Santiago Gil, Elena Ruı́z, Ann-Margaret Little, Alasdair McWhinnie, Alejandro Madrigal. (2003) Unrelated umbilical cord blood transplants in adults: Early recoveryof neutrophils by supportive co-transplantation of a low number of highlypurified peripheral blood CD34+ cells from an HLA-haploidentical donor. Experimental Hematology 31:6, 535-544
CrossRef212
Shunro Kai, Hiroshi Hara. (2003) Allogeneic Hematopoietic Stem Cell Transplantation. Therapeutic Apheresis and Dialysis 7:3, 285-291
CrossRef213
Enrico Danzer, Wolfgang Holzgreve, Carolyn Troeger, Ulrike Kostka, Sabine Steimann, Johanes Bitzer, Alois Gratwohl, Andre Tichelli, Kurt Seelmann, Daniel V. Surbek. (2003) Attitudes of Swiss mothers toward unrelated umbilical cord blood banking 6 months after donation. Transfusion 43:5, 604-608
CrossRef214
Hiroyasu Inoue, Yukiharu Yasuda, Kinya Hattori, Takashi Shimizu, Masae Matsumoto, Miharu Yabe, Hiromasa Yabe, Fumiko Tsuchida, Yumiko Tanaka, Gaku Hosoi, Masahiro Sako, Shunichi Kato. (2003) The Kinetics of Immune Reconstitution after Cord Blood Transplantation and Selected cd34+ Stem Cell Transplantation in Children: Comparison with Bone Marrow Transplantation. International Journal of Hematology 77:4, 399-407
CrossRef215
Chantal Proulx, Lucie Boyer, Darin R. Hurnanen, Real Lemieux. (2003) Preferential Ex Vivo Expansion of Megakaryocytes from Human Cord Blood CD34+-Enriched Cells in the Presence of Thrombopoietin and Limiting Amounts of Stem Cell Factor and Flt-3 Ligand. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 12:2, 179-188
CrossRef216
Guillermo F. Sanz, Vanderson Rocha. (2003) Umbilical cord blood transplantation: current status and future directions. Current Opinion in Organ Transplantation 8:1, 109-117
CrossRef217
William Hwang Ying Khee, Patrick Tan Huat Chye, Tan Cheng Hoe, How Gee Fung, Heng Khee Khiang, Goh Yeow Tee. (2003) Autologous recovery with protractedly undetectable donor chimerisms can precede stable donor engraftment in a nonmyeloablative cord blood transplant. International Journal of Hematology 78:1, 73-75
CrossRef218
Hirokazu Nishihira, Koji Kato, Keiichi Isoyama, Tsuneo A. Takahashi, Shunro Kai, Shunichi Kato, Minoko Takanashi, Norihiro Sato, Hiroyuki Sato, Kohichi Kitajima, Tomoki Naoe, Hidehiko Saito. (2003) The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. British Journal of Haematology 120:3, 516-522
CrossRef219
Cristina V. Navarrete, Jesús Gómez, Francesc E. Borràs. (2003) Cord Blood Dendritic Cells: Subsets, Functional Characteristics and In Vitro Generation. Leukemia & Lymphoma 44:6, 923-928
CrossRef220
C.A. Rusinko, D.A. Sesok-Pizzini. (2003) Using a technological community framework to manage new medical technologies: The case of umbilical cord blood (UCB) banking. Journal of Health Organisation and Management 17:6, 399-421
CrossRef221
Marcos de Lima, Lisa S. St. John, Eric D. Wieder, Ming S. Lee, John McMannis, Safa Karandish, Sergio Giralt, Miroslav Beran, Daniel Couriel, Martin Korbling, Samer Bibawi, Richard Champlin, Krishna V. Komanduri. (2002) Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. British Journal of Haematology 119:3, 773-776
CrossRef222
Young-Ho Lee, Jin-Yeong Han, Su-Yeong Seo, Kyeong-Hee Kim, Young-Ah Lee, Hyung-Sik Lee, Woo-Joo Hur, Hun Han, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim. (2002) Urokinase could increase the yield of progenitor cells during red cell depletion in elapsed and anticoagulated cord blood. American Journal of Hematology 71:4, 336-339
CrossRef223
Nicolas Forraz, Ruth Pettengell, Pierre-Antoine Deglesne, Colin P. McGuckin. (2002) AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis. British Journal of Haematology 119:2, 516-524
CrossRef224
Bruno Nobili, Gabriele Rossi, Piero De Stefano, Marco Zecca, Giovanna Giorgiani, Silverio Perrotta, Anna Canazzio, Franco Locatelli. (2002) Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. British Journal of Haematology 119:2, 573-574
CrossRef225
Suzanne Kadereit, Linda S. Deeds, Stephen E. Haynesworth, Omer N. Koc, Margaret M. Kozik, Emese Szekely, Kathleen Daum‐Woods, Glenn W. Goetchius, Pingfu Fu, Lisbeth A. Welniak, William J. Murphy, Mary J. Laughlin. (2002) Expansion of LTC‐ICs and Maintenance of p21 and BCL‐2 Expression in Cord Blood CD34 + /CD38 − Early Progenitors Cultured over Human MSCs as a Feeder Layer. Stem Cells 20:6, 573-582
CrossRef226
Hermann Eichler, Christian Beck, Bernd Schroder, Xuan Duc Nguyen, Harald Kluter. (2002) Nonobese diabetic-severe combined immunodeficient mice transplantation of volume-reduced and thawed umbilical cord blood transplants following closed-system immunomagnetic cell selection. Transfusion 42:10, 1285-1292
CrossRef227
Dorothy E. Vawter, Gayl Rogers-Chrysler, Mary Clay, Larrie Pittelko, Dave Therkelsen, Debora Kim, Jeffrey McCullough. (2002) A phased consent policy for cord blood donation. Transfusion 42:10, 1268-1274
CrossRef228
Paul R. Haut, Lydia Gonzalez-Ryan, Ling-Jia Wang, Marie Olszewski, Elaine Morgan, Morris Kletzel. (2002) Induction of a transient graft vs. leukemia effect following unrelated cord blood transplantation. Pediatric Transplantation 6:4, 348-351
CrossRef229
Marcos de Lima, Elizabeth J. Shpall. (2002) Cord blood transplantation. Current Opinion in Organ Transplantation 7:3, 286-293
CrossRef230
Hitomi Nagayama, Jun Ooi, Akira Tomonari, Tohru Iseki, Arinobu Tojo, Kenzaburo Tani, Tsuneo A. Takahashi, Naohide Yamashita, Shigetaka Asano. (2002) Severe Immune Dysfunction after Lethal Neutron Irradiation in a JCO Nuclear Facility Accident Victim. International Journal of Hematology 76:2, 157-164
CrossRef231
Robin E Miller, John D Fayen, Shaden F Mohammad, Kevin Stein, Suzanne Kadereit, Kathleen Daum Woods, R.Michael Sramkoski, James W Jacobberger, Dennis Templeton, Susan B Shurin, Mary J Laughlin. (2002) Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes. Experimental Hematology 30:7, 738-744
CrossRef232
Makoto Yazaki, Toshitada Takahashi, Keigo Mizutani, Yasuhiko Ito, Hiroshi Wakiguchi, Masami Inoue, Keisei Kawa, Koji Kato, Toro Kato, Hidehiko Saito, Hajime Togari. (2002) Human leucocyte antigen-Cw-specific cytotoxic T lymphocytes generated from naive cord blood used for cord blood stem cell transplantation. British Journal of Haematology 117:4, 893-898
CrossRef233
Norbert-Claude Gorin, Steven Piantadosi, Margaret Stull, Helene Bonte, John R. Wingard, Curt Civin. (2002) Increased Risk of Lethal Graft-Versus-Host Disease-like Syndrome after Transplantation into NOD/SCID Mice of Human Mobilized Peripheral Blood Stem Cells, As Compared to Bone Marrow or Cord Blood. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:2, 277-292
CrossRef234
Juliet N. Barker, John E. Wagner. (2002) Umbilical cord blood transplantation: current state of the art. Current Opinion in Oncology 14:2, 160-164
CrossRef235
Hadar Marcus, Benjamin Dekel, Fabian D. Arditti, Shlomit Reich-Zeliger, Harry Segal, Wulf O. Bocher, Yair Reisner. (2002) T cells from newborn humans are fully capable of developing into cytotoxic T lymphocyte effector cells in adoptive hosts. Transplantation 73:5, 803-810
CrossRef236
Norbert Schmitz, John Barrett. (2002) Optimizing engraftment-source and dose of stem cells. Seminars in Hematology 39:1, 3-14
CrossRef237
Yuka Hirose, Hitoshi Kiyoi, Katsuhiko Itoh, Koji Kato, Hidehiko Saito, Tomoki Naoe. (2001) B-cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells. Immunology 104:4, 410-417
CrossRef238
Rüdiger V Sorg, Stefanie Andres, Gesine Kögler, Johannes Fischer, Peter Wernet. (2001) Phenotypic and functional comparison of monocytes from cord blood and granulocyte colony-stimulating factor–mobilized apheresis products. Experimental Hematology 29:11, 1289-1294
CrossRef239
Vanderson Rocha, Marie-Vonique Carmagnat, Sylvie Chevret, Odile Flinois, Henrique Bittencourt, Hélène Esperou, Federico Garnier, Patricia Ribaud, Agnès Devergie, Gérard Socié, Liliane Dal'Cortivo, Jean-Pierre Marolleau, Dominique Charron, Eliane Gluckman, Claire Rabian. (2001) Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Experimental Hematology 29:11, 1347-1352
CrossRef240
Thomas G. Gross, R. Maarten Egeler, Franklin O. Smith. (2001) PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Hematology/Oncology Clinics of North America 15:5, 795-808
CrossRef241
Masayuki Oki, Kiyoshi Ando, Masao Hagihara, Hiroko Miyatake, Takashi Shimizu, Hiroyuki Miyoshi, Yoshihiko Nakamura, Hideyuki Matsuzawa, Tadayuki Sato, Yoko Ueda, Balgansuren Gansuvd, Shunichi Kato, Tomomitsu Hotta. (2001) Efficient lentiviral transduction of human cord blood CD34+ cells followed by their expansion and differentiation into dendritic cells. Experimental Hematology 29:10, 1210-1217
CrossRef242
Fernando Marco, Encarna Bureo, Arancha Bermúdez, Elena Fernández-Fontecha, Alberto Zubizarreta. (2001) Treatment of acute leukemia in children: recent advances and future challenges. Expert Review of Anticancer Therapy 1:3, 479-486
CrossRef243
Akihiko Nomura, Hidetoshi Takada, Cheng-Hao Jin, Tamami Tanaka, Shouichi Ohga, Toshiro Hara. (2001) Functional analyses of cord blood natural killer cells and T cells. Experimental Hematology 29:10, 1169-1176
CrossRef244
Z Brahmi, G Hommel-Berrey, F Smith, B Thomson. (2001) NK cells recover early and mediate cytotoxicity via perforin/granzyme and Fas/FasL pathways in umbilical cord blood recipients. Human Immunology 62:8, 782-790
CrossRef245
P. Bugert, W. Zieger, H. Kluter, H. Eichler. (2001) Prenatal HLA typing of uncultured amniocytes prior to the collection of related allogeneic cord blood. Tissue Antigens 58:2, 103-106
CrossRef246
Rafael Bornstein, Jose Garcia-Vela, Florinda Gilsanz, Claude Auray, Carmela Cales. (2001) Cord blood megakaryocytes do not complete maturation, as indicated by impaired establishment of endomitosis and low expression of G1/S cyclins upon thrombopoietin-induced differentiation. British Journal of Haematology 114:2, 458-465
CrossRef247
Suzanne Kadereit, Margaret M Kozik, Gwendolyn R Junge, Robin E Miller, Laura F Slivka, Linda S Bos, Kathleen Daum-Woods, R.Michael Sramkoski, James W Jacobberger, Mary J Laughlin. (2001) Cyclosporin A effects during primary and secondary activation of human umbilical cord blood T lymphocytes. Experimental Hematology 29:7, 903-909
CrossRef248
Tim Niehues, Vanderson Rocha, Alexandra H. Filipovich, Ka Wah Chan, Raphael Porcher, Gerard Michel, Juan J. Ortega, Peter Wernet, Ulrich Gobel, Eliane Gluckman, Franco Locatelli. (2001) Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children - a Eurocord analysis. British Journal of Haematology 114:1, 42-48
CrossRef249
H. Joachim Deeg. (2001) Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction. International Journal of Hematology 74:1, 26-32
CrossRef250
Gluckman, Eliane, . (2001) Hematopoietic Stem-Cell Transplants Using Umbilical-Cord Blood. New England Journal of Medicine 344:24, 1860-1861
Full Text251
Laughlin, Mary J., Barker, Juliet, Bambach, Barbara, Koc, Omer N., Rizzieri, David A., Wagner, John E., Gerson, Stanton L., Lazarus, Hillard M., Cairo, Mitchell, Stevens, Cladd E., Rubinstein, Pablo, Kurtzberg, Joanne, . (2001) Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors. New England Journal of Medicine 344:24, 1815-1822
Full Text252
Marcos De Lima, Richard Champlin. (2001) UNRELATED DONOR HEMATOPOIETIC TRANSPLANTATION. Reviews in Clinical and Experimental Hematology 5:2, 100-134
CrossRef253
Eliane Gluckman, Vanderson Rocha, Sylvie Chevret. (2001) RESULTS OF UNRELATED UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION. Reviews in Clinical and Experimental Hematology 5:2, 87-99
CrossRef254
Francesc E. Borras, Nick C. Matthews, Mark W. Lowdell, Cristina V. Navarrete. (2001) Identification of both myeloid CD11c+ and lymphoid CD11c- dendritic cell subsets in cord blood. British Journal of Haematology 113:4, 925-931
CrossRef255
S. El Marsafy, C. Dosquet, M-C. Coudert, A. Bensussan, E. Carosella, E. Gluckman. (2001) Study of cord blood natural killer cell suppressor activity. European Journal of Haematology 66:4, 215-220
CrossRef256
Mitchell S. Cairo. (2001) Myelopoietic Growth Factors After Stem Cell Transplantation: Does It Pay. Journal of Pediatric Hematology/Oncology 23:1, 2-6
CrossRef257
H. Joachim Deeg. (2000) Graft-versus-host disease: facts and thoughts on recent developments. Current Opinion in Organ Transplantation 5:4, 352-357
CrossRef258
Franklin O. Smith, Blythe G. Thomson, Hal E. Broxmeyer. (2000) Umbilical cord blood transplantation. Current Opinion in Organ Transplantation 5:4, 358-365
CrossRef259
William Reed, Mark Walters, Bertram H. Lubin. (2000) Collection of Sibling Donor Cord Blood for Children With Thalassemia. Journal of Pediatric Hematology/Oncology 22:6, 602-604
CrossRef260
Eliane Gluckman, Franco Locatelli. (2000) Umbilical cord blood transplants. Current Opinion in Hematology 7:6, 353-357
CrossRef261
Robert G Edwards. (2000) A well-taken opportunity for double blessing. Reproductive BioMedicine Online 1:2, 32-33
CrossRef
